Sarepta Therapeutics, Inc. - Common Stock (NQ:SRPT)

18.21 +0.71 (+4.06%)

Delayed Quote Updated: 4:00 PM EDT, Oct 8, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Sarepta Therapeutics, Inc. - Common Stock

< Previous 1 2

...

17 18 19 20 21 22 23 24 25

...

36 37 Next >

Muscle Disease Drug Developer Dyne Therapeutics Stock Plunges After Updated Data From Duchenne Muscular Dystrophy ↗

September 03, 2024

Dyne Therapeutics revealed new clinical data from its Phase 1/2 DELIVER trial of DYNE-251 for Duchenne muscular dystrophy, showing significant increases in dystrophin expression and meaningful...

Via Benzinga

Dyne Called Its Sarepta-Rivaling Results 'Unprecedented,' But Its C-Suite Just Fled The Building ↗

September 03, 2024

The company is hoping to rival Sarepa's Exondys 51. But three executives just departed on what is calls "unprecedented" test results.

Via Investor's Business Daily

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

August 30, 2024

From Sarepta Therapeutics, Inc.

Via Business Wire

Sarepta Therapeutics to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference

August 30, 2024

From Sarepta Therapeutics, Inc.

Via Business Wire

How Is The Market Feeling About Sarepta Therapeutics? ↗

August 16, 2024

Via Benzinga

A Closer Look at 28 Analyst Recommendations For Sarepta Therapeutics ↗

August 15, 2024

Via Benzinga

$100 Invested In This Stock 10 Years Ago Would Be Worth $600 Today ↗

August 12, 2024

Via Benzinga

This Early-Stage Biotech Stock Is Up 400% — Should You Buy Now?

August 19, 2024

Avidity Biosciences' stock has performed incredibly well in 2024. Its Duchenne muscular dystrophy drug is showing strong results in trials.

Via MarketBeat

2 Biotech Stocks to Buy Hand Over Fist in August ↗

August 12, 2024

Both of these biotechs are highly innovative companies.

Via The Motley Fool

Warner Bros, Airbnb And Monster Beverage Are Among Top 10 Large Cap Losers Last Week (Aug 4-Aug 10): Are The Others In Your Portfolio? ↗

August 11, 2024

These 10 stocks had the biggest drop last week, with McKesson Corporation, BIO-TECHNE Corp, and Warner Bros. Discovery, Inc. being the worst performers.

Via Benzinga

How Avidity Biosciences Just Dropped The Hammer On Sarepta Therapeutics ↗

August 09, 2024

The company is coming up fast with a platform that could take on several of Sarepta's approved treatments.

Via Investor's Business Daily

Smart Money Is Betting Big In SRPT Options ↗

August 08, 2024

Via Benzinga

NASDAQ:SRPT may be ready to breakout. ↗

August 02, 2024

NASDAQ:SRPT may be ready to breakout.

Via Chartmill

26 Analysts Have This To Say About Sarepta Therapeutics ↗

July 29, 2024

Via Benzinga

Here's How Much $1000 Invested In Sarepta Therapeutics 10 Years Ago Would Be Worth Today ↗

July 18, 2024

Via Benzinga

McKesson Reports Weak Sales, Joins JFrog, Fastly, Warner Bros. Discovery And Other Big Stocks Moving Lower In Thursday's Pre-Market Session ↗

August 08, 2024

Via Benzinga

7 Biotech Stocks to Buy for Their Game-Changing Potential ↗

August 08, 2024

Although the market may be reeling from the recent fallout, the red ink presents a viable opportunity in these biotech stocks.

Via InvestorPlace

Sarepta Therapeutics (SRPT) Q2 2024 Earnings Call Transcript ↗

August 08, 2024

SRPT earnings call for the period ending June 30, 2024.

Via The Motley Fool

Topics Earnings

SRPT Stock Earnings: Sarepta Therapeutics Beats EPS, Misses Revenue for Q2 2024 ↗

August 07, 2024

SRPT stock results show that Sarepta Therapeutics beat analyst estimates for earnings per share but missed on revenue for the second quarter of 2024.

Via InvestorPlace

Sarepta Therapeutics Announces Second Quarter 2024 Financial Results and Recent Corporate Developments

August 07, 2024

From Sarepta Therapeutics, Inc.

Via Business Wire

Here's How Much $100 Invested In Sarepta Therapeutics 10 Years Ago Would Be Worth Today ↗

July 04, 2024

Via Benzinga

3 Genomics Stocks That May Transform Personalized Medicine ↗

August 06, 2024

These are three of the best genomics stocks to buy for a lucrative entry into a specialized section of the biotech industry.

Via InvestorPlace

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

July 31, 2024

From Sarepta Therapeutics, Inc.

Via Business Wire

Sarepta Therapeutics to Announce Second Quarter 2024 Financial Results

July 29, 2024

From Sarepta Therapeutics, Inc.

Via Business Wire

SAVA Stock Plunges as Cassava Sciences CEO Steps Down. What to Know. ↗

July 17, 2024

The CEO of Cassava Sciences is stepping down, effective immediately. Here's what this means for troubled SAVA stock.

Via InvestorPlace

Jim Cramer Says Don't Sell Match Group: 'You've Just Got A Very, Very Smart Investor In There' ↗

July 17, 2024

Jim Cramer doesn't favor Fortinet, but owns Palo Alto Networks for charity. Air Products not doing well due to better run company Linde.

Via Benzinga

Cassava Sciences Announces Changes in Executive Leadership, Enhanced Corporate Governance and Other Initiatives

July 17, 2024

From Cassava Sciences, Inc.

Via GlobeNewswire

After a Big Win, Is Sarepta Therapeutics Stock a Buy? ↗

July 06, 2024

One key issue remains unresolved, and it could be a significant one.

Via The Motley Fool

Has Sarepta Therapeutics Become a No-Brainer Stock Buy After This Recent FDA News? ↗

July 04, 2024

The label expansion paves the way for much more revenue growth for Sarepta in the years ahead.

Via The Motley Fool

1 Soaring Growth Stock to Buy and Hold for 10 Years ↗

July 03, 2024

Let's look beyond the biotech's performance this year.

Via The Motley Fool

< Previous 1 2

...

17 18 19 20 21 22 23 24 25

...

36 37 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.